<DOC>
	<DOCNO>NCT01855750</DOCNO>
	<brief_summary>The purpose study evaluate ibrutinib administer combination rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ( R-CHOP ) improve clinical outcome newly diagnose patient non-germinal center B-cell subtype ( GCB ) diffuse large B-cell lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>A Study Bruton 's Tyrosine Kinase Inhibitor , PCI-32765 ( Ibrutinib ) , Combination With Rituximab , Cyclophosphamide , Doxorubicin , Vincristine , Prednisone Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>This randomize ( individual assign study treatment chance ) , double-blind ( individual study personnel know identity study treatment ) , placebo ( inactive substance compare drug test whether drug real effect clinical trial ) -controlled study compare efficacy safety ibrutinib combination R-CHOP versus R-CHOP alone adult patient newly diagnose non-GCB DLBCL . The study include screening , active treatment , posttreatment follow-up phase . The study end 50 % participant die sponsor terminates study , whichever occur first ( approximately 7 year ) . Approximately 800 participant randomly assign 1:1 ratio receive either placebo+R-CHOP ( treatment arm A ) ibrutinib+R-CHOP ( treatment arm B ) . All participant receive R-CHOP background therapy 6 8 cycle ( 21 day per cycle ) prespecified accord local practice . After 4 treatment cycle , interim response assessment perform evaluate disease progression participant . Participants progressive disease relapse disease complete response discontinue treatment . Participants discontinue R-CHOP without disease progression continue study drug ( placebo ibrutinib ) 6 8 cycle complete , disease progression , unacceptable toxicity , whichever occur first . After completion study drug , participant undergo assessment tumor response base Revised Response Criteria Malignant Lymphoma . Participants document residual disease upon completion least 6 cycle R-CHOP therapy consider eligible initiate subsequent antilymphoma therapy . Serial pharmacokinetic sample collect dosing , safety monitor throughout study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>No prior treatment diffuse Bcell lymphoma ( DLBCL ) Histologicallyconfirmed nongerminal center Bcell subtype DLBCL Stage II ( candidate local xray therapy ) , III , IV disease Ann Arbor Classification At least 1 measurable site disease accord Revised Response Criteria Malignant Lymphoma Revised International Prognostic Index score &gt; =1 Eastern Cooperative Oncology Group performance status grade 0 , 1 , 2 Hematology biochemical laboratory value within protocoldefined parameter prior random assignment baseline Left ventricular ejection fraction within institutional normal limit , determine echocardiography multiple uptake gated acquisition ( MUGA ) scan Agrees protocoldefined use effective contraception ( woman , restriction apply 12 month last dose rituximab 1 month last dose study drug , whichever later ; men , restriction apply 12 month last dose rituximab 3 month last dose study drug , whichever later ) Men must agree donate sperm study 12 month last dose rituximab 3 month last dose study drug , whichever later Women childbearing potential must negative serum urine pregnancy test screen Major surgery within 4 week random assignment Known central nervous system primary mediastinal lymphoma Prior history indolent lymphoma Diagnosed treated malignancy DLBCL , except : malignancy treat curative intent know active disease present &gt; =3 year random assignment ; adequately treat nonmelanoma skin cancer lentigo maligna without evidence disease ; adequately treat carcinoma situ without evidence disease History stroke intracranial hemorrhage within 6 month prior random assignment Requires anticoagulation warfarin equivalent vitamin K antagonists Requires treatment strong CYP3A inhibitor Prior anthracycline use &gt; =150 mg/m2 Clinically significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 ( moderate ) Class 4 ( severe ) cardiac disease define New York Heart Association Functional Classification Known history human immunodeficiency virus active hepatitis C virus active hepatitis B virus infection uncontrolled active systemic infection require intravenous antibiotic Women pregnant breastfeed Any lifethreatening illness , medical condition , organ system dysfunction , investigator 's opinion , could compromise patient 's safety , interfere absorption metabolism ibrutinib capsule , put study outcome undue risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>B-cell lymphoma</keyword>
	<keyword>Non-germinal center B-cell subtype</keyword>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>Bruton 's tyrosine kinase inhibitor</keyword>
	<keyword>PCI-32765</keyword>
	<keyword>JNJ-54179060</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Prednisone</keyword>
</DOC>